TMS is a non-invasive treatment option works by stimulating neurons in the brain that regulate mood. Image credit: Shutterstock/ShannonChocolate.

California’s Medicaid healthcare programme, Medi-Cal, has added coverage for transcranial magnetic stimulation (TMS) therapy in adults and adolescents aged 15 and older with major depressive disorder (MDD).

The policy update will go into effect on 1 August 2024.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Neuronetics is currently the only company to have a US Food and Drug Administration (FDA)-cleared TMS system for the treatment of adolescents.

California’s new policy means TMS is covered by 17 US state Medicaid programmes.

The National Institute of Mental Health (NIMH) estimates that 21 million adults in the US had at least one major depressive episode in 2021. In the same year, 5 million US adolescents aged 12 to 17 in had at least one major depressive episode.

See Also:

Neuronetics won FDA clearance in March this year for its NeuroStar device as an add-on therapy to antidepressant therapy in adolescent patients with MDD. The therapy is a non-invasive option for MDD patients who do not respond to antidepressant medications. The treatment works by stimulating neurons in the brain that regulate mood.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Neuronetics CEO Keith Sullivan said: “At a time when mental health services are more essential than ever, expanded access to NeuroStar TMS through Medi-Cal is a pivotal step in addressing the growing need for care among both adults and adolescents.”

“NeuroStar’s Health Policy team is fully committed to collaborating with providers and payors on policy updates that enhance availability for those in need.”

Also in the TMS space is BrainsWay, who are investigating a new type of magnetic technology. The company’s rotational field TMS system increases the number of neurons that are activated during therapy, in the fields of rehabilitation following stroke and obsessive-compulsive disorder (OCD).